Menu Close

Trending

Pfizer seeks to overturn three RSV vaccine patents held by GSK
Bayer launches digital AI platform for radiology specialists
Pfizer and Roivant launch autoimmune specialist Priovant
US panel backs Omicron-targeting vaccines for booster campaigns
Pharma’s post-pandemic launch performance problem: what’s the prognosis?
ASCO Kantar coverage_header_03_06_2016

 

ASCO

Kantar_ASCO Day 5 coverage pic
in Partner Content

Ibrance approval cemented as competition comes into view

X
Ibrance approval cemented as competition comes into view
https://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/

In February 2015,  Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed

PP_ASCO Day 4 coverage pic
in ASCO-slider

Eye on ASCO Day 4 – Moonshots, Money and Mobile apps

X
Eye on ASCO Day 4 – Moonshots, Money and Mobile apps
https://pharmaphorum.com/event-coverage/asco-slider/day-4-moonshots-money-and-mobile-apps/

You don’t often get searched by the US secret service at a medical meeting.

Kantar_ASCO Day 4 coverage pic
in Partner Content

Does NEMO bring us a step closer in the fight against melanoma?

X
Does NEMO bring us a step closer in the fight against melanoma?
https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/

Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in

Kantar_ASCO Day 4 coverage pic
in Partner Content

The HNSCC immunotherapy race is on – and it’s going to be close

X
The HNSCC immunotherapy race is on – and it’s going to be close
https://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/

While improper to compare life saving treatments to buses – the metaphor when it comes to head and

PP_ASCO Day 3 coverage pic
in Views and analysis

Eye on ASCO Day 3 – Pricey combos cause panic

X
Eye on ASCO Day 3 – Pricey combos cause panic
https://pharmaphorum.com/views-and-analysis/eye-on-asco-day-2-pricey-combos-cause-panic/

But is it pharma’s fault?

Kantar_ASCO Day 3 coverage pic
in Partner Content

Further Darzalex results extend hope for PFS in Myeloma

X
Further Darzalex results extend hope for PFS in Myeloma
https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

Login

CONTINUE TO SITE >
X
Close in 10 seconds